Literature DB >> 27632567

Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia.

Muhamed Baljevic1, Bogdan Dumitriu, Ju-Whei Lee, Elisabeth M Paietta, Peter H Wiernik, Janis Racevskis, Christina Chen, Eytan M Stein, Robert E Gallagher, Jacob M Rowe, Frederick R Appelbaum, Bayard L Powell, Richard A Larson, Steven E Coutré, Jeffrey Lancet, Mark R Litzow, Selina M Luger, Neal S Young, Martin S Tallman.   

Abstract

Telomeres are the capping ends of chromosomes that protect the loss of genetic material and prevent chromosomal instability. In human tissue-specific stem/progenitor cells, telomere length (TL) is maintained by the telomerase complex, which consists of a reverse transcriptase catalytic subunit (TERT) and an RNA template (TERC). Very short telomeres and loss-of-function mutations in the TERT and TERC genes have been reported in acute myeloid leukemia, but the role of telomeres in acute promyelocytic leukemia (APL) has not been well established. We report the results for a large cohort of 187 PML/RARα-positive APL patients. No germline mutations in the TERT or TERC genes were identified. Codon 279 and 1062 TERT polymorphisms were present at a frequency similar to that in the general population. TL measured in blood or marrow mononuclear cells at diagnosis was significantly shorter in the APL patients than in healthy volunteers, and shorter telomeres at diagnosis were significantly associated with high-risk disease. For patients who achieved complete remission, the median increase in TL from diagnosis to remission (delta TL) was 2.0 kilobase (kb), and we found delta TL to be the most powerful predictor of overall survival when compared with well-established risk factors for poor outcomes in APL.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27632567      PMCID: PMC5198772          DOI: 10.1159/000448160

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  25 in total

1.  Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia.

Authors:  Rodrigo T Calado; Joshua A Regal; Mark Hills; William T Yewdell; Leandro F Dalmazzo; Marco A Zago; Peter M Lansdorp; Donna Hogge; Stephen J Chanock; Elihu H Estey; Roberto P Falcão; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2009-01-15       Impact factor: 11.205

2.  X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions.

Authors:  N S Heiss; S W Knight; T J Vulliamy; S M Klauck; S Wiemann; P J Mason; A Poustka; I Dokal
Journal:  Nat Genet       Date:  1998-05       Impact factor: 38.330

3.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

4.  Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure.

Authors:  Tom J Vulliamy; Amanda Walne; Aroon Baskaradas; Philip J Mason; Anna Marrone; Inderjeet Dokal
Journal:  Blood Cells Mol Dis       Date:  2005 May-Jun       Impact factor: 3.039

5.  Additional chromosome abnormalities confer worse prognosis in acute promyelocytic leukaemia.

Authors:  L R Hiorns; G J Swansbury; J Mehta; T Min; M G Dainton; J Treleaven; R L Powles; D Catovsky
Journal:  Br J Haematol       Date:  1997-02       Impact factor: 6.998

Review 6.  Curing all patients with acute promyelocytic leukemia: are we there yet?

Authors:  Muhamed Baljevic; Jae H Park; Eytan Stein; Dan Douer; Jessica K Altman; Martin S Tallman
Journal:  Hematol Oncol Clin North Am       Date:  2011-12       Impact factor: 3.722

Review 7.  Telomere diseases.

Authors:  Rodrigo T Calado; Neal S Young
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

8.  Retinoid/arsenic combination therapy of promyelocytic leukemia: induction of telomerase-dependent cell death.

Authors:  I Tarkanyi; C Dudognon; J Hillion; F Pendino; M Lanotte; J Aradi; E Ségal-Bendirdjian
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

9.  Telomerase activity and telomere length in patients with acute promyelocytic leukemia: indicative of proliferative activity, disease progression, and overall survival.

Authors:  S H Ghaffari; N Shayan-Asl; A H Jamialahmadi; K Alimoghaddam; A Ghavamzadeh
Journal:  Ann Oncol       Date:  2008-06-20       Impact factor: 32.976

Review 10.  Cancer in dyskeratosis congenita.

Authors:  Blanche P Alter; Neelam Giri; Sharon A Savage; Philip S Rosenberg
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

View more
  3 in total

Review 1.  Biological and clinical implications of telomere dysfunction in myeloid malignancies.

Authors:  Ashwin Kishtagari; Justin Watts
Journal:  Ther Adv Hematol       Date:  2017-10-06

Review 2.  Telomere Length and Hematological Disorders: A Review.

Authors:  Beatriz Maria Dias Nogueira; Caio Bezerra Machado; Raquel Carvalho Montenegro; Maria Elisabete Amaral DE Moraes; Caroline Aquino Moreira-Nunes
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

3.  TERT rs2853669 as a predictor for overall survival in patients with acute myeloid leukaemia.

Authors:  Florin Tripon; Claudia Bănescu; Adrian P Trifa; Andrei G Crauciuc; Valeriu G Moldovan; Alina Boglis; Istvan Benedek; Smaranda Demian; Carmen Duicu; Mihaela Iancu
Journal:  Arch Med Sci       Date:  2021-03-18       Impact factor: 3.318

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.